The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology radiotherapy medical oncology pathology radiology gastroenterology).

  • English
  • Dutch
Current path: Home » > Publications

CAIRO 2

- Tol J, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FLG, Vos AH, Mol L, Antonini NF, Punt CJA. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO 2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734-8

- Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL,  Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72

- Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009 Jul 2;361:98-9.

- Tol J, Punt CJA. Recent developments in the treatment of advanced colorectal cancer. Eur Gastroenterol Rev 2006;12-16.

- Tol J, Cats A, Koopman M, Bos M, van Krieken JHJM, Punt CJA. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation Invest New Drugs 2008;26:393-7

- Punt CJ. Tol J. More is less – Combining targeted therapies in colorectal cancer. Nature Rev Clin Oncol 2009;6:731-3

- Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Desch CE, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Meropol NJ. The relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26;3213-21.

- Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009:20:1223-9.   

- Mannaerts L, Bleeker-Rovers CP, Koopman M, Punt CJ, van Herpen CM. Pylephlebitis after a duodenal ulcer in a patient with metastasised colon carcinoma treated with chemotherapy and bevacizumab: a case report. Neth J Med 2009;67:69-71.

- Tol J, Nagtegaal ID, Punt CJA. Een combinatie van antilichamen bij gemetastaseerd colon- en rectumcarcinoom leidt tot een slechtere progressievrije overleving: de CAIRO2-studie van de Dutch Colorectal Cancer Group. Ned Tijdschr Oncol 2009;6;196-200

- Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJM, Vos AH, Nagtegaal ID, Terstappen LWMM and Punt CJA. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010;21:1006-12

- Tol J, Dijkstra JR, Vink-Börger ME, Nagtegaal ID, Punt CJ, van Krieken JH, Ligtenberg MJ. High sensitivity of both sequencing and real-time PCR analysis of  KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2010;14:2122-31

- Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink- Börger ME, van Cleef PH, van Krieken JH, Punt CJA, Nagtegaal ID. Markers of EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with and without cetuximab. Eur J Cancer 2010;46:1997-2009

- Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JHJM, van der Straaten T, Punt CJA, Guchelaar HJ. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010; 46:1829-34

- Knijn N, Tol J, Koopman M, Werter MJBP, de Klerk G, van Bochove A, Mol L, Vincent AD, Punt CJA.The effect of prophylactic calcium and magnesium infusions  on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based chemotherapy, bevacizumab and cetuximab in advanced colorectal cancer patients. Eur J Cancer 2010;47:369-74

- Simkens L, Tol J, Terstappen LWMM, Teerenstra S, Punt CJA, Nagtegaal ID. The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. Ann Oncol 2010;12:2447-8

- Pander J, Wessels JAM,  Gelderblom H, van der Straaten T, Punt CJA, Guchelaar HJ. Pharmacogenetic interaction analysis for the efficacy of capecitabine, oxaliplatin and bevacizumab in metastatic colorectal cancer. Ann Oncol 2011;22:1147-53

- de Krijger I, Mekenkamp LJ, Punt CJ, Nagtegaal ID. MicroRNAs in colorectal cancer metastasis. J Pathol 2011;224:438-47

Back to top


Site navigation

Back to top


The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology radiotherapy medical oncology pathology radiology gastroenterology).